| Prev Close | 2.56 |
| Open | 2.60 |
| Day Low/High | 2.57 / 2.74 |
| 52 Wk Low/High | 1.46 / 7.85 |
| Volume | 41.68K |
| Avg Volume | 110.30K |
| Exchange | AMEX |
| Shares Outstanding | 14.08M |
| Market Cap | 36.04M |
| EPS | -0.40 |
| P/E Ratio | 4.20 |
| Div & Yield | N.A. (N.A) |
Latest News
Can-Fite Receives Notice Of Allowance For Psoriasis Patent In Europe Ahead Of Phase III Trial
- 2.4 million Europeans living with moderate-to-severe psoriasis
Can-Fite Completes Phase II Study Design For CF102 In The Treatment Of NASH/NAFLD
- NASH/NAFLD are the leading cause of liver disease in Western countries
Can-Fite Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects
- Similar to biologics, Piclidenoson (CF101) inhibits inflammatory proteins IL-17 and IL-23
Can-Fite Submits Psoriasis Phase III Protocol And Registration Plan To EMA For Piclidenoson (CF101)
- Phase III protocol is a head-to-head trial comparing Piclidenoson to Otezla®
Can-Fite To Exhibit At Bio International Convention In San Francisco On June 6-9, 2016
Company also to participate as a member of the Israeli Biotech Delegation at Perspectives on Biotech Investing on June 6
Can-Fite Reaches Agreement With EMA On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis
- EMA suggests development of Piclidenoson as a first line therapy and alternative for methotrexate, the standard of care for rheumatoid arthritis
Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data
Can-Fite BioPharma (CANF) stock is gaining on Monday afternoon as the company announced pre-clinical data for CF602, which demonstrated statistically significant full recovery from erectile dysfunction after a single dose.
Can-Fite Announces New Pre-Clinical Data For CF602 Demonstrating Statistically Significant Full Recovery From Erectile Dysfunction After A Single Dose
CF602 may provide benefits for patients who cannot take or do not respond to erectile dysfunction drugs currently on the market
Can-Fite Submits Phase III Protocol Design And Registration Plan To European Medicines Agency (EMA) For CF101 In The Treatment Of Rheumatoid Arthritis
Trial expected to commence in Q2/3 of 2016
Can-Fite To Present Psoriasis Data At American Academy Of Dermatology's 74th Annual Meeting In Washington D.C. On March 7, 2016
Phase III psoriasis study expected to commence in 2016
Can-Fite CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016
Dr. Fishman is one of a select number of global Key Opinion Leaders on drugs targeting A3AR receptors
U.S. Patent & Trademark Office Issues Notice Of Allowance For Can-Fite's Sexual Dysfunction Drug CF602
- Composition of matter patent protects use of an A3AR modulator for the treatment of any indication
Can-Fite Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications
- Phase III trials in rheumatoid arthritis and psoriasis expected to commence in 2016
Can-Fite Submits Phase III Protocol To IRB For CF101 In The Treatment Of Rheumatoid Arthritis
- Pivotal Phase III trial to enroll approximately 456 patients for robust statistically significant data
Can-Fite's CF101 Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma
- CF101's Phase II glaucoma trial recently completed enrollment- Glaucoma market is estimated to reach $3 billion by 2023
OphthaliX Announces CF101 Is Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma
- CF101's Phase II glaucoma trial recently completed enrollment
Can-Fite Subsidiary, OphthaliX, Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101
CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in 2023
OphthaliX Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101
CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in 2023
Can-Fite Announces Compelling Pre-Clinical Data On CF102 In The Treatment Of Non-Alcoholic Steatohepatitis (NASH)
- Files patent for CF102 in the treatment of NASH
